NCT00646191 - Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

137

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

June 30, 2004

Conditions

Psoriasis

Interventions

DRUG

adalimumab

40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse

DRUG

adalimumab

40 mg weekly through Week 48 (OL Week 12 - 48)

DRUG

adalimumab

80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse